TG Therapeutics, Inc. (TGTX) Cash Flow Statement
TG Therapeutics, Inc. (TGTX) generated $17.9M of operating cash flow over the twelve months to 2026-06-30, spent $491000 on capital expenditure and had free cash flow of $17.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TGTXTG Therapeutics, Inc.Follow TGTX — free
—
Price chart with a free account
- Market cap
- 8.3B
- P/E TTM
- 19.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.13 | -0.13 | -0.21 | -0.30 | -0.18 | -0.03 | -0.04 | -0.02 | 0.02 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | -0.13 | -0.13 | -0.21 | -0.30 | -0.18 | -0.03 | -0.04 | -0.02 | 0.02 | |
| Stock-based compensation | 0.01 | 0.01 | 0.08 | 0.06 | 0.04 | 0.04 | 0.04 | 0.06 | — |
USD billions · SEC XBRL
TG Therapeutics, Inc. — questions
- What is TG Therapeutics, Inc.'s operating cash flow?
- $17.9M over the twelve months to 2026-06-30.
- How much does TG Therapeutics, Inc. spend on capital expenditure?
- $491000 over the twelve months to 2026-06-30.
- What is TG Therapeutics, Inc.'s free cash flow?
- $17.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from TG Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.